Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019
The R&D Day will feature presentations by
A live webcast of the event will be available under "Events and Presentations" in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 90 days following the event.
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We are currently advancing three investigational medicines in clinical development, along with multiple research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-host-rd-day-and-announce-third-quarter-2019-financial-results-on-november-5-2019-300946897.html
Jim Baker, Vice President, Corporate Affairs, 617-844-8236, email@example.com; Kristin Hodous, Senior Manager, Investor Relations, 617-714-6674, firstname.lastname@example.org